Unique ID issued by UMIN | UMIN000030252 |
---|---|
Receipt number | R000034550 |
Scientific Title | The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence. |
Date of disclosure of the study information | 2017/12/11 |
Last modified on | 2021/01/13 17:38:32 |
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.
The efficacy of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.
The efficacy of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.
Japan |
Abdominal pain and abdominal fullness feeling in the patients with fecal incontinence
Gastroenterology |
Others
NO
To evaluate the efficacy and the safety of Daikenchuto on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.
Safety,Efficacy
1) Numeric Rating Scale (NRS) of abdominal pain
2) NRS of abdominal fullness feeling
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
Daikenchuto (15g/day) for 4 weeks
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients who have faecal incontinence of 2-4 times/4 weeks or more in the past 6 months
2)Patients who have abdominal pain or abdominal fullness feeling
3)Age: Aged 20 and over
4)Mini Mental State Examination (MMSE)>=11
5)Patients for whom oral administration was possible
6)Patients who provided written informed consent regarding study participation.
1)Patients who have anal sphincter injury
2)Patients who have severe mental illness
3)Patients who can not perform their daily activities
4)Suspected organic disease such as the cancer in gastrointestinal tract
5)Presence of serious complications (liver, kidney, heart, or blood disease or metabolic disease)
6)Patients who took drugs prohibited for concomitant use 2 weeks before entry.
7)History of allergic reactions to Kampo medicines
8)Pregnant or lactating women or those who are planning to conceive during the study period
9)Considered ineligible to participate by principal investigator or sub-investigator
50
1st name | Kazufumi |
Middle name | |
Last name | Shimazutsu |
Medical Corporation Seiaikai, Gion Ushita Hospital
Gion Ushita Hospital
731-0113
8-29-24 nishihara, asa minami-ku, hiroshima
082-850-3116
stratmagic@mac.com
1st name | Kazufumi |
Middle name | |
Last name | Shimazutsu |
Medical Corporation Seiaikai, Gion Ushita Hospital
Gion Ushita Hospital
731-0113
8-29-24 nishihara, asa minami-ku, hirosima
082-850-3116
stratmagic@mac.com
Medical Corporation Seiaikai, Gion Usshita Hospital
Tsumura & Co.
Profit organization
Hiroshima University Certified Review Board
1-2-3, Kasumi, MInami-ku, Hiroshima City
082-257-1551
iryo-seisaku@office.hiroshima-u.ac.jp
NO
ぎおん牛田病院(広島県)
2017 | Year | 12 | Month | 11 | Day |
Unpublished
Completed
2017 | Year | 12 | Month | 01 | Day |
2020 | Year | 01 | Month | 30 | Day |
2017 | Year | 12 | Month | 11 | Day |
2019 | Year | 03 | Month | 04 | Day |
2017 | Year | 12 | Month | 04 | Day |
2021 | Year | 01 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034550